NCT03525418View on ClinicalTrials.gov

Lomecel-B Delivered During Stage II Surgery for Hypoplastic Left Heart Syndrome (ELPIS)

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 21, 2018

Primary Completion Date

June 30, 2024

Study Completion Date

December 31, 2025

Conditions
HLHS
Interventions
BIOLOGICAL

Longeveron Mesenchymal Stem Cells

Allogeneic bone marrow-derived mesenchymal stem cell

Trial Locations (5)

21201

University of Maryland Medical Center, Baltimore

21287

Johns Hopkins University Hospital, Baltimore

30307

Emory University/Childen's Healthcare of Atlanta, Atlanta

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

84113

University of Utah/Heart Center-Primary Children's Hospital, Salt Lake City

Sponsors

Lead Sponsor

Longeveron Inc.
All Listed Sponsors
lead

Longeveron Inc.

INDUSTRY

NCT03525418 - Lomecel-B Delivered During Stage II Surgery for Hypoplastic Left Heart Syndrome (ELPIS) | Biotech Hunter | Biotech Hunter